These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

888 related items for PubMed ID: 29675794

  • 1. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
    Kamamoto D, Ohara K, Kitamura Y, Yoshida K, Kawakami Y, Sasaki H.
    J Neurooncol; 2018 Sep; 139(2):251-259. PubMed ID: 29675794
    [Abstract] [Full Text] [Related]

  • 2. A review of solitary fibrous tumor/hemangiopericytoma tumor and a comparison of risk factors for recurrence, metastases, and death among patients with spinal and intracranial tumors.
    Giordan E, Marton E, Wennberg AM, Guerriero A, Canova G.
    Neurosurg Rev; 2021 Jun; 44(3):1299-1312. PubMed ID: 32556679
    [Abstract] [Full Text] [Related]

  • 3. Surveillance for metastatic hemangiopericytoma-solitary fibrous tumors-systematic literature review on incidence, predictors and diagnosis of extra-cranial disease.
    Ratneswaren T, Hogg FRA, Gallagher MJ, Ashkan K.
    J Neurooncol; 2018 Jul; 138(3):447-467. PubMed ID: 29551003
    [Abstract] [Full Text] [Related]

  • 4. Clinical outcomes of intracranial solitary fibrous tumor and hemangiopericytoma: analysis according to the 2016 WHO classification of central nervous system tumors.
    Kim BS, Kim Y, Kong DS, Nam DH, Lee JI, Suh YL, Seol HJ.
    J Neurosurg; 2018 Dec 01; 129(6):1384-1396. PubMed ID: 29372881
    [Abstract] [Full Text] [Related]

  • 5. Analyses of prognosis-related factors of intracranial solitary fibrous tumors and hemangiopericytomas help understand the relationship between the two sorts of tumors.
    Zeng L, Wang Y, Wang Y, Han L, Niu H, Zhang M, Ke C, Chen J, Lei T.
    J Neurooncol; 2017 Jan 01; 131(1):153-161. PubMed ID: 27671018
    [Abstract] [Full Text] [Related]

  • 6. Analysis of the inflammatory tumor microenvironment in meningeal neoplasms.
    Berghoff AS, Kresl P, Rajky O, Widhalm G, Ricken G, Hainfellner JA, Marosi C, Birner P, Preusser M.
    Clin Neuropathol; 2020 Jan 01; 39(6):256-262. PubMed ID: 32831157
    [Abstract] [Full Text] [Related]

  • 7. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
    Lim YJ, Koh J, Kim K, Chie EK, Kim B, Lee KB, Jang JY, Kim SW, Oh DY, Bang YJ, Ha SW.
    Radiother Oncol; 2015 Oct 01; 117(1):165-70. PubMed ID: 26235847
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY, Au WL, Lo KY, Ni YB, Hlaing T, Hu J, Chan SK, Chan KF, Cheung SY, Tse GM.
    Breast Cancer Res Treat; 2017 Feb 01; 162(1):19-30. PubMed ID: 28058578
    [Abstract] [Full Text] [Related]

  • 10. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N, Azuma M, Ikarashi M, Yamamoto M, Sato M, Watanabe KI, Yamashiro K, Takahashi M.
    Breast Cancer; 2018 Jan 01; 25(1):34-42. PubMed ID: 28488168
    [Abstract] [Full Text] [Related]

  • 11. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
    Liu P, Xiao Q, Zhou B, Dai Z, Kang Y.
    World Neurosurg; 2019 Sep 01; 129():e240-e254. PubMed ID: 31128313
    [Abstract] [Full Text] [Related]

  • 12. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
    Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW, Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B, Mittelbronn M.
    Oncotarget; 2015 Dec 01; 6(38):40836-49. PubMed ID: 26517811
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A DSTYK mutation activates ERK1/2 signaling to promote intraspinal dissemination in a case of solitary fibrous tumor/hemangiopericytoma.
    Tang G, Yang Y, Shang L, Jun F, Liu Q.
    Lab Invest; 2019 Oct 01; 99(10):1501-1514. PubMed ID: 31201369
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Programmed Death Ligand 1: A Step Toward Immunoscore for Esophageal Cancer.
    Hynes CF, Kwon DH, Vadlamudi C, Lofthus A, Iwamoto A, Chahine JJ, Desale S, Margolis M, Kallakury BV, Watson TJ, Haddad NG, Marshall MB.
    Ann Thorac Surg; 2018 Oct 01; 106(4):1002-1007. PubMed ID: 29859152
    [Abstract] [Full Text] [Related]

  • 17. [Solitary fibrous tumor/hemangiopericytoma of central nervous system: a clinicopathologic analysis of 71 cases].
    Li XL, Fu WW, Zhang S, Chen DY, Chen YP, Wu J, Liu XY, Li GP, Lin SM, Luo S, Cai SS, Guo W, Wang XF.
    Zhonghua Bing Li Xue Za Zhi; 2017 Jul 08; 46(7):465-470. PubMed ID: 28728219
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.